Rights to antibody drug from China’s Keymed change hands in Gilead acquisition of Ouro
•US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal wo...
•Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines.
•Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion...
هذا الخبر من South China Morning Post. خبر يقدم أدوات ذكاء اصطناعي للتلخيص والترجمة والاستماع.
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal worth up to US$2.18 billion. Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines. Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion...المصدر: South China Morning Post | Source: South China Morning Post
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة South China Morning Post. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by South China Morning Post. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
